File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Prophylaxis and treatment of recurrent hepatitis B after liver transplantation

TitleProphylaxis and treatment of recurrent hepatitis B after liver transplantation
Authors
Issue Date2003
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.transplantjournal.com
Citation
Transplantation, 2003, v. 75 n. 3 SUPPL., p. S41-S44 How to Cite?
AbstractChronic hepatitis B virus (HBV) infection is the leading cause of end-stage liver disease in Asia. The results of liver transplantation in these patients have significantly improved to a level comparable to those of other recipients as a result of the rapid evolution in the strategies of prevention and treatment of recurrent hepatitis B over the past decade. Hepatitis B immune globulin (HBIG) and lamivudine, either alone or in combination, are effective in preventing reinfection, but the most cost-effective dosing regimen with optimum efficacy without the prohibitive cost remains to be determined, an issue that is particularly relevant to liver transplant centers with serious financial constraints in Asia. The idea of active immunization is attractive, but the results have been conflicting to date. The newer nucleoside analogs appear most promising, and a combination of two or more antiviral agents is likely to represent the future strategy of choice in the prophylaxis and treatment of recurrent hepatitis B after liver transplantation.
Persistent Identifierhttp://hdl.handle.net/10722/77064
ISSN
2015 Impact Factor: 3.69
2015 SCImago Journal Rankings: 1.699
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLo, CMen_HK
dc.contributor.authorFan, STen_HK
dc.contributor.authorLiu, CLen_HK
dc.contributor.authorLai, CLen_HK
dc.contributor.authorWong, Jen_HK
dc.date.accessioned2010-09-06T07:27:53Z-
dc.date.available2010-09-06T07:27:53Z-
dc.date.issued2003en_HK
dc.identifier.citationTransplantation, 2003, v. 75 n. 3 SUPPL., p. S41-S44en_HK
dc.identifier.issn0041-1337en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77064-
dc.description.abstractChronic hepatitis B virus (HBV) infection is the leading cause of end-stage liver disease in Asia. The results of liver transplantation in these patients have significantly improved to a level comparable to those of other recipients as a result of the rapid evolution in the strategies of prevention and treatment of recurrent hepatitis B over the past decade. Hepatitis B immune globulin (HBIG) and lamivudine, either alone or in combination, are effective in preventing reinfection, but the most cost-effective dosing regimen with optimum efficacy without the prohibitive cost remains to be determined, an issue that is particularly relevant to liver transplant centers with serious financial constraints in Asia. The idea of active immunization is attractive, but the results have been conflicting to date. The newer nucleoside analogs appear most promising, and a combination of two or more antiviral agents is likely to represent the future strategy of choice in the prophylaxis and treatment of recurrent hepatitis B after liver transplantation.en_HK
dc.languageengen_HK
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.transplantjournal.comen_HK
dc.relation.ispartofTransplantationen_HK
dc.rightsTransplantation. Copyright © Lippincott Williams & Wilkins.en_HK
dc.subject.meshAntiviral Agents - therapeutic useen_HK
dc.subject.meshDrug Therapy, Combinationen_HK
dc.subject.meshHepatitis B - prevention & control - surgery - therapyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshImmunizationen_HK
dc.subject.meshImmunoglobulins - therapeutic useen_HK
dc.subject.meshLamivudine - therapeutic useen_HK
dc.subject.meshLiver Transplantationen_HK
dc.subject.meshPreventive Medicine - methodsen_HK
dc.subject.meshRecurrence - prevention & controlen_HK
dc.subject.meshReverse Transcriptase Inhibitors - therapeutic useen_HK
dc.titleProphylaxis and treatment of recurrent hepatitis B after liver transplantationen_HK
dc.typeConference_Paperen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0041-1337&volume=75&spage=S41&epage=S44&date=2003&atitle=Prophylaxis+and+treatment+of+recurrent+hepatitis+B+after+liver+transplantationen_HK
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.emailLai, CL: hrmelcl@hku.hken_HK
dc.identifier.emailWong, J: jwong@hkucc.hku.hken_HK
dc.identifier.authorityLo, CM=rp00412en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.identifier.authorityWong, J=rp00322en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid12589139-
dc.identifier.scopuseid_2-s2.0-0037442103en_HK
dc.identifier.hkuros77124en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0037442103&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume75en_HK
dc.identifier.issue3 SUPPL.en_HK
dc.identifier.spageS41en_HK
dc.identifier.epageS44en_HK
dc.identifier.isiWOS:000181167000013-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLo, CM=7401771672en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK
dc.identifier.scopusauthoridLiu, CL=7409789712en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK
dc.identifier.scopusauthoridWong, J=8049324500en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats